Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma

To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of irinotecan and raltitrexed given as sequential short infusions every 3 weeks, 33 patients with pretreated gastrointestinal adenocarcinoma (31 colorectal, 2 oesophagogastric) entered this open label dose-escalation st...

Descripción completa

Detalles Bibliográficos
Autores principales: Ford, H E R, Cunningham, D, Ross, P J, Rao, S, Aherne, G W, Benepal, T S, Price, T, Massey, A, Vernillet, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363476/
https://www.ncbi.nlm.nih.gov/pubmed/10901362
http://dx.doi.org/10.1054/bjoc.2000.1192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363476/
https://www.ncbi.nlm.nih.gov/pubmed/10901362
http://dx.doi.org/10.1054/bjoc.2000.1192

Ejemplares similares